RankAlpha logo

VVOS

Rating neutralTentativeAI Memo

Vivos Therapeutics

As of 2026-11-11/Confidence medium
Data freshness
AI Memo
As of 2026-11-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice
Coverage is limited for this name. This memo is usable, but confidence is lower and evidence depth is thinner than a standard report.
Action
neutral
Confidence
medium
Horizon
—
Key catalyst
Next filing must substantiate Nasdaq equity compliance • 2026-11-30
Base target: $0 / p=40% prob
Biggest risk
Liquidity, operating losses, potential common-share issuance and the need to demonstrate continuing Nasdaq compliance could overwhelm revenue growth. The October transaction adds preferred-conversion complexity without immediate cash proceeds. [#SEC-8K-2026-10-19] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047601/form8-k.htm
Invalidation
Break below $0 or thesis failure.
What would change my mind?
Nevada sleep-service growth and the conditional restoration of Nasdaq equity compliance improve the operating and listing outlook. The SOD interest offers optionality, but no commercialization revenue is established. [#PR-2026-08-14] https://www.globenewswire.com/news-release/2026/08/14/3345627/0/en/vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-operational-update.html [#8-K-2026-10-21] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047841/form8-k.htm
Research note
Recommendation
neutral
Confidence
medium
As of
2026-11-11
Base target
$0
p=40%
Bull target
$0
p=20%
Bear target
$0
p=40%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets
  • Debt exchange and preferred shares create dilution risk
  • Sleep-service growth needs to reduce cash burn
  • Pseudohypoxia test requires commercial proof
BearKey bullets
  • June 30 cash was $1.8 million against a Q2 net loss of $5.5 million, leaving substantial financing risk.
  • [#PR-2026-08-14] https://www.globenewswire.com/news-release/2026/08/14/3345627/0/en/vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-operational-update.html
  • Nasdaq’s equity-compliance determination may be revisited after the next periodic report.
WatchKey bullets
  • Next filing must substantiate Nasdaq equity compliance

Summary

High-level snapshot

Recommendation
neutral
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
-
Base case: $0 (p=40%)
Target spread vs base: +100% / -62%
Scenario probabilities
Bull Target: $0 (p=20%)Base Target: $0 (p=40%)Bear Target: $0 (p=40%)
Commentary
Recent company filings improve the prior listing-compliance picture but leave dilution and cash funding central. News coverage is thin. The packet supplies no verified recent analyst revisions, post-announcement price-reaction attribution, social coverage or dependable positioning measures; zero-valued sentiment fields denote unavailable inputs, not neutral readings.
As of 2026-11-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case
Nevada sleep-service growth and the conditional restoration of Nasdaq equity compliance improve the operating and listing outlook. The SOD interest offers optionality, but no commercialization revenue is established. [#PR-2026-08-14] https://www.globenewswire.com/news-release/2026/08/14/3345627/0/en/vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-operational-update.html [#8-K-2026-10-21] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047841/form8-k.htm
Bear Case
Liquidity, operating losses, potential common-share issuance and the need to demonstrate continuing Nasdaq compliance could overwhelm revenue growth. The October transaction adds preferred-conversion complexity without immediate cash proceeds. [#SEC-8K-2026-10-19] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047601/form8-k.htm

Drivers

Scannable catalysts and supporting factors

  • Debt exchange and preferred shares create dilution risk
  • Sleep-service growth needs to reduce cash burn
  • Pseudohypoxia test requires commercial proof

Scenarios

Bull Target (Scenario probability)
$0 / p=20% prob
Base Target (Scenario probability)
$0 / p=40% prob
Bear Target (Scenario probability)
$0 / p=40% prob
Analysis 2026-11-11 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)
0.00
Social Sentiment (7d)
0.00

Events

Other notable items detected

  • EVENT2026-11-30
    Next filing must substantiate Nasdaq equity compliance
    Nasdaq determined on October 20 that Vivos met its minimum stockholders’ equity requirement, but warned that failure to evidence compliance in its next periodic report could lead to delisting proceedings. This resolves the earlier deficiency only conditionally. [#8-K-2026-10-21] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047841/form8-k.htm
    Prob 75.00% • Move 15.00% • Priced-in 60.00%

Short-term Catalysts

Next few weeks

  • Debt exchange and preferred shares create dilution risk
    2026-12-31
    An August agreement provides for exchange of $2.86 million of note principal for up to 11.45 million common shares. The October SOD transaction was paid with convertible preferred stock rather than cash. Share issuance terms and selling pressure could outweigh debt relief or strategic benefits. [#8-K-2026-09-08] https://www.sec.gov/Archives/edgar/data/1716166/000149315226041616/form8-k.htm [#SEC-8K-2026-10-19] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047601/form8-k.htm
    Prob 80% • Move -25% • Priced-in 65%

Long-term Catalysts

Months to a year

  • Sleep-service growth needs to reduce cash burn
    2027-06-30
    Company-reported Q2 revenue rose 35% to $5.2 million, driven by Nevada sleep-testing and treatment services, but June cash was only $1.8 million. Sustained service growth matters only if it improves funding needs. [#PR-2026-08-14] https://www.globenewswire.com/news-release/2026/08/14/3345627/0/en/vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-operational-update.html
    Prob 40% • Move 30% • Priced-in 30%
  • Pseudohypoxia test requires commercial proof
    2027-12-31
    Vivos completed an acquisition of at least 11% of SOD Sciences and 50% co-ownership of its pseudohypoxia test intellectual property. The filing establishes ownership, not regulatory approval, adoption or revenue; commercialization evidence is the relevant future test. [#SEC-8K-2026-10-19] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047601/form8-k.htm
    Prob 30% • Move 20% • Priced-in 20%

Risks

  • June 30 cash was $1.8 million against a Q2 net loss of $5.5 million, leaving substantial financing risk. [#PR-2026-08-14] https://www.globenewswire.com/news-release/2026/08/14/3345627/0/en/vivos-therapeutics-reports-second-quarter-2026-financial-results-and-provides-operational-update.html
  • Nasdaq’s equity-compliance determination may be revisited after the next periodic report. [#8-K-2026-10-21] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047841/form8-k.htm
  • The August note-exchange agreements permit issuance of up to 11.45 million common shares, subject to their terms. [#8-K-2026-09-08] https://www.sec.gov/Archives/edgar/data/1716166/000149315226041616/form8-k.htm
  • The SOD test interest is not evidence of regulatory clearance, commercial demand or near-term revenue. [#SEC-8K-2026-10-19] https://www.sec.gov/Archives/edgar/data/1716166/000149315226047601/form8-k.htm

Peers

SymbolSummary
BDMDSimilar-sized health-care-equipment microcap, but a different device market; useful for financing-risk context, not a direct operating multiple.
CODXSimilar-sized health-care-equipment name, but diagnostics differs from Vivos’ sleep-treatment and services model. Not a direct valuation peer.

Sources

Internal and external references used in this analysis

  • Model source: RankAlpha Sentiment Codex
  • Analysis date: 2026-11-11